Recent data from the FOURIER trial have addressed clinical concerns regarding low lipoprotein(a) safety in patients with atherosclerotic cardiovascular disease. While high levels of Lipoprotein(a) drive heart disease risk, many physicians worry about potential side effects from extremely low concentrations. Consequently, this secondary analysis focused on safety outcomes like bleeding and cognitive function in over 25,000 participants.

Evidence Supporting Low Lipoprotein(a) Safety

The study found no link between low Lp(a) levels and risks of haemorrhagic stroke, serious bleeding, or malignancy. Moreover, participants with levels as low as 13 nmol/L showed no increased incidence of atrial fibrillation or neurocognitive events. These results provide significant reassurance to clinicians. Specifically, the data suggest that aggressive lowering of this lipoprotein does not compromise neurological or vascular integrity.

However, the relationship with diabetes mellitus remains complex. While a lower baseline concentration was associated with a higher prevalence of diabetes, it did not predict a higher risk of developing new-onset diabetes during the trial. Therefore, the metabolic profile of these patients requires monitoring, yet the overall safety remains high. Furthermore, these findings support the continued development of targeted Lp(a) therapies.

Frequently Asked Questions

Does low Lp(a) increase the risk of diabetes?

Data show that while patients with naturally low Lp(a) may have a higher prevalence of diabetes at baseline, lowering Lp(a) with medication does not appear to increase the risk of developing new-onset diabetes.

Is it safe to lower Lp(a) to very low levels?

Yes, the FOURIER trial indicates that very low levels of Lp(a) are not associated with increased risks of stroke, bleeding, cancer, or cognitive decline, supporting its long-term safety profile.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional recommendation. Always consult a qualified healthcare provider for personal health concerns. Refer to the latest local and national guidelines for clinical practice.

References

1. Gencer B et al. Safety of low lipoprotein(a) levels: the FOURIER trial. Eur Heart J. 2026 Jun 03. doi: undefined. PMID: 42234492.


2. Sabatine MS et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713-1722.


3. O'Donoghue ML et al. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation. 2019;139(12):1483-1492.